Protection from Combined Vivotif and Dukoral Vaccination
Taking both Vivotif (oral typhoid vaccine Ty21a) and Dukoral (oral cholera vaccine) provides dual protection: approximately 50-69% efficacy against typhoid fever and 85% efficacy against cholera, with the vaccines maintaining their individual protective effects when administered together.
Individual Vaccine Protection
Vivotif (Typhoid Vaccine Ty21a)
When administered as a complete 4-dose regimen on alternate days, Vivotif provides:
- Cumulative 3-year efficacy: 50% (95% CI 35%-61%) against typhoid fever 1, 2
- Protection persists for at least 5 years after vaccination 1
- The 4-dose schedule is superior to 2 or 3 doses, with significantly lower typhoid incidence 2
Dukoral (Cholera Vaccine)
This killed whole-cell vaccine with recombinant cholera toxin B subunit offers:
- 85% protection against cholera caused by Vibrio cholerae 3
- 67% protection against heat-labile enterotoxigenic E. coli (ETEC), a common cause of travelers' diarrhea 3
- Up to 43% protection against travelers' diarrhea in general 3
Combined Administration
The vaccines can be safely co-administered without compromising individual efficacy 4. Research demonstrates:
- Seroconversion rates remain robust: 87-94% for cholera (Inaba vibriocidal antibodies) and 72-91% for typhoid (anti-S. typhi lipopolysaccharide antibodies) when given in combination 4
- The bivalent approach maintains the immunogenicity of both vaccine strains 4
Critical Timing Consideration
Important caveat: Based on expert opinion regarding potential buffer interference, take the first Vivotif dose at least 8 hours after Dukoral to prevent the cholera vaccine buffer from interfering with the enteric-coated typhoid capsule 5. This timing recommendation is based on the mechanism of how the buffer in the cholera vaccine might compromise the acid-resistant coating of Ty21a.
Mechanism of Protection
Both vaccines work through different but complementary mechanisms:
- Vivotif: Induces local intestinal immunity through an aborted infection with live attenuated bacteria, eliciting both humoral anti-S. typhi LPS antibody responses and likely cellular immunity 2
- Dukoral: Provides both anti-bacterial immunity (from killed whole cells) and anti-toxic immunity (from recombinant CTB), with both components essential for full protection 6
Adverse Events Profile
The combination maintains the favorable safety profile of both vaccines:
- Side effects are similar in type and frequency to monovalent vaccines 4
- Ty21a: Minimal adverse effects (abdominal discomfort, nausea occur at placebo rates) 1
- Dukoral: Negligible adverse events 3
Duration and Boosters
- Vivotif: Revaccination with full 4-dose series recommended every 5 years for continued protection 1
- Dukoral: No booster data currently available for the CVD 103-HgR formulation; duration beyond 3 months post-vaccination is unknown 5
Drug Interactions to Avoid
Critical precautions:
- Antibiotics: Do not give Vivotif within 14 days of antibiotic use (may kill vaccine strain) 5
- Chloroquine: May reduce Dukoral immunogenicity; start chloroquine ≥10 days after vaccination 5
- Proguanil: May reduce Vivotif immunogenicity 4
Bottom line: This combination provides comprehensive protection for travelers to endemic areas where both typhoid and cholera are risks, with each vaccine maintaining its protective efficacy when properly timed and administered according to the full dosing schedule.